Al M J, Koopmanschap M A, van Enckevort P J, Geertsma A, van der Bij W, de Boer W J, TenVergert E M
Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands.
Chest. 1998 Jan;113(1):124-30. doi: 10.1378/chest.113.1.124.
To calculate cost-effectiveness of scenarios concerning lung transplantation in The Netherlands.
Microsimulation model predicting survival, quality of life, and costs with and without transplantation program, based on data of the Dutch lung transplantation program of 1990 to 1995.
Netherlands, University Hospital Groningen.
Included were 425 patients referred for lung transplantation, of whom 57 underwent transplantation.
Lung transplantation.
For the baseline scenario, the costs per life-year gained are G 194,000 (G=Netherlands guilders) and the costs per quality-adjusted life-year (QALY) gained are G 167,000. Restricting patient inflow ("policy scenario") lowers the costs per life-year gained: G 172,000 (costs per QALY gained: G 144,000). The supply of more donor lungs could reduce the costs per life-year gained to G 159,000 (G 135,000 per QALY gained; G1 =US $0.6, based on exchange rate at the time of the study).
Lung transplantation is an expensive but effective intervention: survival and quality of life improve substantially after transplantation. The costs per life-year gained are relatively high, compared with other interventions and other types of transplantation. Restricting the patient inflow and/or raising donor supply improves cost-effectiveness to some degree. Limiting the extent of inpatient screening or lower future costs of immunosuppressives may slightly improve the cost-effectiveness of the program.
计算荷兰肺移植相关方案的成本效益。
基于1990年至1995年荷兰肺移植项目的数据,建立微观模拟模型以预测有或无移植项目情况下的生存率、生活质量和成本。
荷兰格罗宁根大学医学中心。
纳入425名被转诊进行肺移植的患者,其中57人接受了移植。
肺移植。
对于基线方案,每获得一个生命年的成本为194,000荷兰盾(荷兰盾),每获得一个质量调整生命年(QALY)的成本为167,000荷兰盾。限制患者流入量(“政策方案”)可降低每获得一个生命年的成本:172,000荷兰盾(每获得一个QALY的成本:144,000荷兰盾)。增加供体肺的供应可将每获得一个生命年的成本降至159,000荷兰盾(每获得一个QALY的成本为135,000荷兰盾;根据研究时的汇率,1荷兰盾 = 0.6美元)。
肺移植是一种昂贵但有效的干预措施:移植后生存率和生活质量有显著改善。与其他干预措施和其他类型的移植相比,每获得一个生命年的成本相对较高。限制患者流入量和/或增加供体供应在一定程度上可提高成本效益。限制住院筛查范围或降低未来免疫抑制剂的成本可能会略微提高该项目的成本效益。